Clinical and contrast-enhanced ultrasonographic characteristics of peripheral lung masses in patients infected with human immunodeficiency virus
10.12025/j.issn.1008-6358.2025.20241397
- VernacularTitle:人类免疫缺陷病毒感染患者周围型肺肿块的临床与超声造影特征分析
- Author:
Lei ZHAO
1
;
Jingjing HUANG
1
;
Xin MA
1
;
Xia SHI
1
;
Dou WU
1
;
Zhi ZHANG
1
;
Fengxiang SONG
2
;
Jianjian LIU
1
Author Information
1. Department of Ultrasonography, Shanghai Public Health Clinical Center, Shanghai 201508, China.
2. Department of Radiology, Shanghai Public Health Clinical Center, Shanghai 201508, China.
- Publication Type:Originalarticle
- Keywords:
peripheral lung mass;
contrast-enhanced ultrasound;
human immunodeficiency virus;
differential diagnosis
- From:
Chinese Journal of Clinical Medicine
2025;32(2):276-282
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical characteristics of human immunodeficiency virus (HIV) infected patients with peripheral lung masses (PLMs), and to assess the diagnostic utility of contrast-enhanced ultrasound (CEUS) in differentiating benign and malignant PLMs. Methods A retrospective analysis was performed on the clinical data of 69 patients with PLM treated in Shanghai Public Health Clinical Center from January 2020 to December 2023. All patients underwent percutaneous biopsy, and were categorized into benign group (n＝36) and malignant group (n＝33). 25 patients were HIV-positive and 44 patients were HIV-negative. The clinical features and CEUS parameters in patients were compared across these groups. Results Patients with malignant masses were significantly older than those with benign masses (P＜0.05). In the malignant group, HIV-negative patients exhibited significantly larger tumor diameters compared to HIV-positive patients (P＜0.05); in the HIV-positive patients, no significant difference in tumor size was observed between benign and malignant masses. 19 patients underwent CEUS. 10 malignant masses, irrespective of HIV status (10 positive and 9 negative), commonly presented with indistinct margins, delayed enhancement, heterogeneous perfusion, and delayed peak enhancement on CEUS. 9 benign masses showed earlier peak enhancement compared to 10 malignant masses (P＜0.05); no significant differences were observed in the initiation and washout time of enhancement between benign and malignant masses. In HIV-positive patients, 5 benign masses frequently demonstrated discrepancies between CEUS findings and pathological results. Conclusions The clinical and CEUS characteristics were different between benign and malignant PLMs. However, CEUS shows limited accuracy in distinguishing benign and malignant PLMs, underscoring the need for pathological confirmation.
